HRTX Q3'26 Earnings: revenue estimate is 37.50M USD

What happened

Heron Therapeutics is set to announce its Q3'26 results on November 9 before the market opens, with disclosure expected at 8:00 a.m. ET. The revenue estimate is 37.50M USD, and earnings per share, or profit or loss for each share, are anticipated to be negative.

Confirmed

Global impact / market context

The results will show whether reported revenue and loss per share match the estimates. A revenue shortfall could mean less cash coming in to support operating costs, while a larger loss could increase pressure to reduce spending or seek additional funding.

Analyst inference

The supplied history shows reported revenue below estimates in three of the four earlier quarters listed, while losses per share also differed from estimates. That pattern makes the upcoming revenue and earnings figures relevant to investors judging whether the company is meeting expectations and how its results are developing.

Analyst inference

What to watch

1. Compare reported quarterly revenue with the 37.50M USD estimate; a shortfall would indicate weaker sales than expected, while a beat would show stronger revenue. Confirmed
2. Check reported earnings per share, meaning profit or loss for each share, against the expected negative result to judge whether losses were larger or smaller than forecast. Confirmed
3. Read any explanation of revenue changes or spending plans; stronger sales or lower costs could improve cash available, while weaker sales or rising costs could pressure it. Analyst inference

Evidence

• Original source link unavailable